Book now
More information to come soon.
Speakers will include:
Session Leaders:
This is a valuable opportunity to explore our wide range of exhibitor stands and network with fellow delegates!
Until a few years ago the trending hashtags were blockchain, real world evidence, and accelerated pathways. Soon after, Parallel advice and HTA Bodies, and Payors came to the fore, suddenly out of nowhere the world was hit with Generative AI. Let’s face it, the healthcare industry never had issues in keeping up with the times and health agencies are no different. Both FDA and EMA have issued guidance relating to the use of AI in 2023. This year the Agencies have also started implementing generative AI in-house. This session aims to shed light on the Agencies’ approach to balancing the need for swift access to groundbreaking treatments with the imperative of ensuring public safety. By fostering an open exchange of ideas, the chat will provide insights into the agencies’ current initiatives, their future directions, and the broader implications for public health policy and practice. Join us for a compelling conversation that promises to deepen our understanding of the complexities at the intersection of healthcare innovation and regulation, and to envision the future of public health in a rapidly evolving landscape.
Electronic Product Information (ePI) holds critical medicinal product information available to patients and healthcare providers almost in real time. Discover current state and factors needed for EU implementation and the overview of the EMA/HMA ePI Pilot Project. Session Leaders:
Session Lead:
Clinical evidence generation for healthcare products has advanced to include a range of approaches. Although clinical trials (CTs) remain the research modality most relied upon by regulatory authorities for establishing clinical safety and efficacy, the lifecycle of evidence generation for medicines and vaccines increasingly embrace a combination of approaches which includes real-world evidence (RWE). Over the last two decades, the EU clinical trials environment has undergone significant changes intended to simplify and harmonize the administrative provisions governing EU clinical trials but obstacles persist that hamper the conduct of multinational trials in the EU. Progress continues to be made to work in partnership to optimize the implementation of the EU CTR and the related launch of the single EU portal and clinical trial database, CTIS. The ACT EU initiative aims to support further transformation of the clinical trials environment in the EU. With several priority actions covering different aspects of clinical trials, the main goal of ACT EU is to contribute to the health of EU citizens through faster access to innovative medicines and optimized use of medicines on the market. Enabling access to innovative new medicines requires a range of approaches to evidence generation over the lifecycle of this product. This session will broaden the conversation on clinical evidence generation beyond traditional silos of clinical trials and real-world evidence generation to consider how we can holistically work in collaboration to generate evidence that meets the needs of decision makers through the product lifecycle. The session will probe the interface between the EMA/HMA’s ACT EU and Big Data Initiatives and how these link into a broader strategic vision for the EU medicines regulatory network. The panel will consider not only how science is evolving but also the complexity of clinical trial execution in a rapidly changing landscape. Session Lead:
How to successfully navigate the new EU HTA Regulation’s mandatory assessment of relative effectiveness occurring in parallel with MAA – earlier consideration of HTA evidence needs during clinical development and regulatory strategy will be key. Session Lead:
Focus of the session will be on practical implementation of the Clinical Trial regulation post transition in a global context. Experience will be shared from usage of CTIS including transparency and disclosure requirements. The session will discuss challenges in navigating between the different EU regulations in relation to clinical trials and elements to consider in navigating a global trial beyond the current fragmented environment. Session Leaders:
No content found